Bringing state-of-the-art technologies to regional Australia.

David has been successful in contributing to the field through a total of 26 publications (senior author 4; first author 11; second author 10 and middle author 1). Collectively, his work has focused on improving the diagnosis and management of platelet related bleeding disorders through descriptions of his experience using genetic sequencing technologies to diagnose these disorders, and via reports detailing phenotypic characteristics and pathophysiological mechanisms of specific disorders caused by pathological genetic variants in genes associated with bleeding.

Dr Rabbolini completed his PhD at USYD in 2018 investigating IPDs using a combined genomic and disease modelling approach employing patient specific induced pluripotent stem cells. His thesis was awarded The Peter Bancroft Prize by the University of Sydney Medical School having being passed by all three examiners without requiring any emendation or amendments.

Dr Rabbolini’s research was awarded the prestigious Australasian Society of Thrombosis and Haemostasis (THANZ) medal in 2015 for contributions to the genetic diagnosis and understanding of FLI1-related thrombocytopenia (RT) and was runner up in 2016 for work relating to the diagnosis GFI1B– RT confirming platelet CD34 expression as biomarker of the disorder.

Dr Rabbolini has been successful in translating his research into the clinical field through the formation of The Sydney Platelet Group that he co-leads. This collaborative provides, through integration of clinical and research platforms, patients with a level of investigation not possible at any other single centre in Australia. He has also led a “first in Australia” pilot study exploring a novel platelet function testing platform called, Optimul, and is the principal investigator supervising its expansion into some regional centres across Australia.

Dr Rabbolini is currently also involved in research exploring coagulation disorders in sepsis, trauma and stroke and is involved with Australian based teams exploring novel ways to detect and treat these coagulation abnormalities.

Below are the publications as cited in “Google Scholar”. See Google Scholar direct for Publications prior to 2018.


Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study
LA Coupland, DJ Rabbolini, JG Schoenecker, PJ Crispin, JJ Miller, …
Critical Care 27 (1), 1-14
Viscoelastometry to Manage Bleeding in Liver Disease

DJR Samantha Wilson, Joanne Joseph, Mark Danta

Prevalence and natural history of variants in the ANKRD26 gene: a short review and update of reported cases
H Vyas, A Alcheikh, G Lowe, WS Stevenson, NV Morgan, DJ Rabbolini
Platelets 33 (8), 1107-1112
The utility of flow cytometric platelet forward scatter as an alternative to mean platelet volume
D Connor, D Rabbolini, MC Morel-Kopp, K Fixter, D Donikian, M Kondo, …
Platelets 33 (8), 1139-1145
A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia

H Hsu, MV Chan, PC Armstrong, M Crescente, D Donikian, M Kondo, …
Pathology 54 (6), 746-754

Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study

A Rosenberg, C Cashion, F Ali, H Haran, RK Biswas, V Chen, H Crowther, …
Research and Practice in Thrombosis and Haemostasis 6 (6), e12792

Building platelet phenotypes: diaphanous-related formin 1 (DIAPH1)-related disorder

D Rabbolini, HPH Liang, MC Morel-Kopp, D Connor, S Whittaker, …
Platelets 33 (3), 432-442

Diagnostic pathway for platelet disorders

D Rabbolini
Pathology 54, S21

Prevalence and natural history of variants in the ANKRD26 gene
H Vyas, A Alcheikh, G Lowe, WS Stevenson, N Morgan, DJ Rabbolini
The Current Role of Platelet Function Testing in Clinical Practice
GA Mason, DJ Rabbolini
Seminars in Thrombosis and Hemostasis
Editorial compilation VIII

G Lippi, R Gosselin, D Adcock, A Dorgalaleh, R Gosselin, D Adcock, …
Seminars in Thrombosis and Hemostasis 46 (04), 393-397

International council for standardization in haematology recommendations for hemostasis critical values, tests, and reporting

D Adcock, A Dorgalaleh, E Favaloro, G Lippi, J Pego, I Regan, V Siguret, …
Seminars in Thrombosis and Hemostasis 46 (04), 398-409

An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group

D Rabbolini, D Connor, MC Morel-Kopp, D Donikian, M Kondo, W Chen, …
Pathology 52 (2), 243-255

The clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy – A case series and review of the literature

C Tang, DJ Rabbolini, MC Morel‐Kopp, DE Connor, P Crispin, CM Ward, …
Research and Practice in Thrombosis and Haemostasis 4 (1), 106-110

Molecular and genetic testing in thrombosis and hemostasis

DJ Rabbolini, M Othman
Seminars in Thrombosis and Hemostasis 45 (07), 657-660

Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

J Joseph, D Rabbolini, AK Enjeti, E Favaloro, MC Kopp, S McRae, …
Medical Journal of Australia 210 (11), 509-516


Member on the editorial Board Review Editor

Frontiers in Medicine (Haematology)

Invited guest co-editor – Special issue of Seminars in Thrombosis and Haemostasis Journal
  • lead co-editor with the responsibility of determining issue content, inviting authors, editing submissions and completing an editorial chapter.

Titles of chapters invited and edited in this issue:

  • Next generation sequencing technologies and new methodologies (Davis et al. Australia)
  • Bioinformatic tools, in silico prediction tools and analysis (Hampshire et al, UK)
  • Genetic techniques used in the diagnosis of inherited platelet disorders (disorders of platelet number and function) (Westbury, UK)
  • Molecular diagnosis of inherited coagulation and bleeding disorders (Bastida et al, Spain)
  • Molecular testing in von Willebrand disease (Batlle et al, Spain)
  • Haemophilia (Goodeve, UK)
    • Genetic and molecular testing in thrombosis and hemostasis: Informing surveillence, treatment and prognosis (Crispin, Australia)
  • Gene editing and gene therapy in thrombosis and haemostasis (Ozelo et al, Brazil)
  • Genetic testing for thrombophilia related genes: a cautionary tale to highlight the growing futility of testing for factor V Leiden and the prothrombin gene ‘mutation’ (Favaloro, Australia)
  • Translational research in thrombosis and haemostasis: application of chromatin structural assays to better understand haemostasis gene expression; single cell sequencing; liquid biopsies (Lillicrap et al, Canada)
ISTH congress daily news scientific editor

Tasked to review and to edit approximately ~25 articles for scientific/clinical accuracy intended for publication during the scientific congress.

Dr Rabbolini also serves as an invited peer reviewer for several scientific journals including:

  • Blood Journal
  • Blood Advances
  • Journal of Thrombosis and Haemostasis (JTH)
  • Haematologica
  • Haemophilia
  • Platelets Journal
  • British Journal of Haematology (BJH)
  • Leukaemia research
  • Pathology Journal
  • Stem Cell Reports
  • Thrombosis Journal
  • American Journal of Hematology
  • Internal Medicine Journal (MJA)



Dr Rabbolini’s experience has been recognised by his peers, and he has been an invited speaker at 13 national and international (UK, Spain and Kenya) conferences and workshops in the last 5 years and has moderated an International Society of Thrombosis and Haemostasis (ISTH) led webinar on Genetics in haemostasis and thrombosis. Dr Rabbolini is actively engaged in research and education and his contributions have been recognised through invitations on a national and international stage. Notable speaker roles have included: